Target intelligence / Profile preview

Polysialoganglioside (PSG)

Target
PSG
Molecular classification
Receptor, Other
01

Overview

Polysialogangliosides are a class of sialic acid-containing glycosphingolipids that are highly concentrated within the presynaptic membranes of the nervous system (Schengrund, 2015). They function as essential co-receptors for clostridial neurotoxins, such as Botulinum and Tetanus toxins, by mediating the initial high-affinity binding required for toxin internalization into neurons (Rummel, 2016). Beyond their role in toxin entry, these molecules are critical for maintaining synaptic integrity, modulating the activity of ion channels, and facilitating cell-to-cell recognition and signaling (Schnaar, 2016). In clinical medicine, they are the functional targets for therapeutic Botulinum neurotoxins used to treat conditions like muscle spasticity, dystonia, and chronic migraine (Pirazzini et al., 2017). Furthermore, polysialogangliosides are significant in the pathogenesis of autoimmune neuropathies, such as Guillain-Barré and Miller Fisher syndromes, where they are targeted by autoantibodies (Willison et al., 2016). Understanding their distribution and binding kinetics is vital for the development of next-generation neurotherapeutics and antitoxins.

Other names
SialoglycosphingolipidComplex gangliosideGT1bGD1bGD1aGQ1bPresynaptic gangliosides
02

Mechanism of action

Acts as a high-affinity binding site for the heavy chain of clostridial neurotoxins, facilitating their entry into the nerve terminal via a dual-receptor mediated endocytosis process.

03

Biological functions

Signal transductionCell-cell recognitionOther
04

Disease associations

InfectionNeurodegenerative diseaseOther
05

Safety considerations

Autoimmune cross-reactivity (Guillain-Barré syndrome)Iatrogenic botulismAntibody-mediated drug resistanceSystemic toxin spread
06

Interacting drugs

OnabotulinumtoxinA

5 more in the full profile.

07

Biomarkers

Anti-GQ1b antibodiesAnti-GT1b antibodiesAnti-GD1b antibodiesAnti-GM1 antibodies

Beyond the preview

Go deeper on Polysialoganglioside (PSG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Polysialoganglioside (PSG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call